Many studies has confirmed the crucial role of thyroid hormone transporters for TH action in human target cells. The importance was better understood by observing the phenotype in patients harboring mutations of the monocarboxylate transporter 8 (MCT8) gene immediately linked to Allan-Herndon-Dudley Syndrome (AHDS), in which severe neurological findings are associated with abnormal Thyroid hormone levels. The disease is X-chromossome linked, with males presenting a homogeneous neurological psychomotor phenotype and mental retardation associated with low serum T 4 and elevated T 3 levels. The mechanism of disease is still obscure and either the physiopathology as the existent therapeutic options need to be better studied.
INTRODUCTION
Correct intracellular T 3 concentration is important for the normal human development and exerts its action on virtually all type of tissues. It has been thought initially that thyroid hormone (TH) entrance into the target cells occurred by passive diffusion through the lipid cell membranes. But it has been found many transporters that selectively facilitates the TH passage across the cell membrane.
(1) The important role of transporters for TH in humans was established by the observations in patients harboring mutations of the monocarboxylate transporter 8 (MCT8) gene which presented severe neurological findings associated with unusual abnormalities in thyroid function. (2, 3) MCT8 is expressed in many tissues throughout the body, including the brain, skeletal muscle, liver and placenta. (1) This contribution illustrates how a genetic disease perturbing the supply of biological active TH to cells affects the development and maturation of the central nervous system.
PATHOPHYSIOLOGY OF THYROID HORMONE CELL-MEMBRANE TRANSPORT DEFECTS
The syndrome has been identified in more than 200 affected males belonging to some 100 families, and only one sporadic case of a female carrying a disrupted MCT8 gene in combination with unfavorable nonrandom X-inactivation. (4) (5) (6) These mutations (OMIM#300523) include large deletions, insertions, nonsense mutations and missense mutations. (4, 5) Some variation of the severity of the can be explained by mutations that cause reduced, but not absent, TH transport. (4, 5, 7) In MCT8 deficient patients, the decreased T 3 supply to neuronally expressed D3 will result in a decreased T 3 clearence. This gives rise to increased serum T 3 , which will stimulate renal and hepatic D1 activity and, thus, increase T 3 production. This increased D1 activity contributes, in part, to the lower T 4 and rT 3 serum levels. (8, 9) The elevated TSH levels despite the high serum T 3 reflects pituitary resistance to T 3 . In contrast, there is evidence for a thyrotoxic state of the liver and skeletal muscle in MCT8 patients, suggesting that TH is taken up by the cells predominantly via other transporters than MCT8.
(
The T 3 entry in some important tissues such as bone, skeletal muscle, heart, liver and intestine might be raised in the presence of high serum levels of T 3 , then it might be observed advanced bone age, muscle wasting, malnutrition and elevation of markers of thyroid hormone action in each organ of MCT8 patients.
(5, 10)
PHENOTYPE OF THYROID HORMONE CELL-MEMBRANE TRANSPORT DEFECTS
The hereditary pattern of MCT8 defect transmission is Mendelian X-chromossome linked, with males presenting a typical neurological psychomotor phenotype, low serum T 4 and reverse T 3 but elevated T 3 and normal or slightly elevated TSH. The main findings in MCT8 patients described in the literature are summarized in Table 1 (4, 5, (10) (11) (12) (13) (14) and consists in the coexistence of hyperthyroid and hypothyroid tissues. The structure of the MCT8 gene is showed in Figure 1 . 
CONCLUSIONS
MCT8 gene mutations produce X-linked mental retardation, congenital hypotonia and spastic quadriplegia in association with typical thyroid test abnormalities. The irreversible severe psychomotor phenotype observed in these patients clearly attests the vital role of TH in human neuronal development. The thyroidal phenotype includes high serum levels of serum T 3 , low levels of reverse T 3 and T 4 and high/ normal levels of TSH. 
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Currently, the management of the disorder is limited to few options and none efficient in correcting the defect. They do not benefit from substitution therapy with L-T 3 and/or L-T 4 , with no changes in the mental and neurological development and administration of supraphysiological doses of TH could provoke impairment of the hypermetabolic state and selective tissue thyrotoxicity. (1, 5) The use of 3,5-diiodothyropropionic acid (DITPA) has been proposed as feasible TH analogue which does not require MCT8 for T 3 transport but binds to TH receptor α and β. (15) To date, the promising thyromimetic effects of high doses of DITPA (1-2 mg/kg · d) in the MCT8 patients tested normalizes the T 3 and TSH levels, associated with T 4 and rT 3 elevation to the lower normal range.
